The Silent Long-Term Damage of Resistant Hypertension: A Clinical Case Report
Abstract
Background/Aim: Resistant hypertension (RH) is a complex clinical condition associated with substantial cardiovascular and renal morbidity. Persistent blood pressure (BP) elevation despite optimal multidrug therapy should prompt a careful search for secondary causes and hypertension-mediated target organ damage. Chronic kidney disease (CKD) and sustained activation of the renin–angiotensin–aldosterone system (RAAS) are frequently involved, often resulting in a prolonged subclinical course. This case report aims to highlight the clinical importance of a structured diagnostic approach to resistant hypertension in the context of a hypertensive emergency.
Case: A 56-year-old man without previous medical follow-up presented with severe hypertension accompanied by headache and epigastric discomfort. BP measurements revealed marked inter-arm differences and values consistent with a hypertensive emergency. Laboratory evaluation showed impaired renal function, hypokalemia, and significant proteinuria. Imaging and echocardiographic assessment demonstrated chronic kidney disease, left ventricular hypertrophy, pulmonary congestion, and ascending aortic dilatation. Further hormonal evaluation revealed elevated renin and aldosterone levels with a low aldosterone to renin ratio, supporting secondary hyperaldosteronism related to CKD and exacerbated by frequent nonsteroidal anti-inflammatory drug use. BP was controlled with intravenous antihypertensive therapy followed by intensive oral multidrug treatment, including diuretics, renin–angiotensin system blockade, and an aldosterone antagonist.
Conclusion: This case demonstrates that long-standing, undiagnosed hypertension may present as a hypertensive emergency accompanied by advanced target organ damage. Hypervolemia and the RAAS play a critical role in the development of RH, particularly when combined with CKD and nonsteroidal anti-inflammatory drug use. Low aldosterone to renin ratio levels, accompanied by elevated renin and aldosterone levels, serve as a valuable marker for ruling out primary adrenal pathology and indicate secondary hyperaldosteronism. Although the difference in BP between the arms initially suggests structural vascular abnormalities, the underlying etiology is RAAS activation triggered by CKD and hypervolemia. This case highlights the importance of regular BP measurements and a systematic approach, including assessment of the RAAS profile, fluid status, and medication history, for accurate diagnosis in RH.
Keywords
References
- Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017;96(7):453-61.
- Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-54. doi:10.1093/eurheartj/eht534.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
- Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386(10003):1588-98. doi:10.1016/S0140-6736(15)00418-3.
- Guthrie B. Can NSAIDs be used safely for analgesia in patients with CKD?: CON. Kidney360. 2020;1(11):1189- 91. doi:10.34067/KID.0005112020.
- Connell JMC, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008;29(2):133-54. doi:10.1210/er.2007-0030.
- Sica DA. Endocrine causes of secondary hypertension. J Clin Hypertens. 2008;10(7):534-40. doi:10.1111/j.1751-7176.2008.08097.x.
- Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. doi:10.1210/jc.2014-1498.
Details
Primary Language
English
Subjects
Internal Diseases
Journal Section
Case Report
Authors
Sertaş Erarslan
0000-0002-6816-4154
Türkiye
Publication Date
April 17, 2026
Submission Date
February 7, 2026
Acceptance Date
March 31, 2026
Published in Issue
Year 2026 Volume: 8